This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/534384-moderna-two-in-covid-flu-shot/
The article has changed 2 times. There is an RSS feed of changes available.
Previous version
1
Next version
| Version 0 | Version 1 |
|---|---|
| Moderna developing two-in-one booster shot for Covid-19 and flu | Moderna developing two-in-one booster shot for Covid-19 and flu |
| (about 1 month later) | |
| Moderna has announced that it is developing a single-dose vaccine to bring to the market that will combine a two-in-one booster shot that protects against both Covid-19 and flu. | Moderna has announced that it is developing a single-dose vaccine to bring to the market that will combine a two-in-one booster shot that protects against both Covid-19 and flu. |
| On Thursday, drugmaker Moderna unveiled its latest innovation in the fight against Covid-19 – a “pan-respiratory annual booster vaccine” that combines a booster against Covid-19 and one against regular flu. | On Thursday, drugmaker Moderna unveiled its latest innovation in the fight against Covid-19 – a “pan-respiratory annual booster vaccine” that combines a booster against Covid-19 and one against regular flu. |
| “Our number one priority as a company right now is to bring to market a pan-respiratory annual booster vaccine, which we plan to always customize and upgrade,” said CEO Stéphane Bancel. | “Our number one priority as a company right now is to bring to market a pan-respiratory annual booster vaccine, which we plan to always customize and upgrade,” said CEO Stéphane Bancel. |
| Moderna is not the first to have announced the creation of a combined jab for Covid-19 and flu. American vaccine-maker Novavax announced on Wednesday that it has started an early stage trial in Australia to test its own two-in-one shot, having enrolled 640 healthy adult volunteers between the ages of 50 and 70. | Moderna is not the first to have announced the creation of a combined jab for Covid-19 and flu. American vaccine-maker Novavax announced on Wednesday that it has started an early stage trial in Australia to test its own two-in-one shot, having enrolled 640 healthy adult volunteers between the ages of 50 and 70. |
| Last week, Moderna submitted data to the European Medicines Agency for conditional approval for its Covid-19 vaccine to be used as a booster shot. Meanwhile, the US Food and Drug Administration greenlighted top-up doses of mRNA vaccines manufactured by Pfizer-BioNTech and Moderna in mid-August for people with compromised immune systems. | Last week, Moderna submitted data to the European Medicines Agency for conditional approval for its Covid-19 vaccine to be used as a booster shot. Meanwhile, the US Food and Drug Administration greenlighted top-up doses of mRNA vaccines manufactured by Pfizer-BioNTech and Moderna in mid-August for people with compromised immune systems. |
| Moderna’s two-dose Covid-19 vaccine boasts a high efficacy rate of 93% six months after the administration of its second shot, barely waning from the 94.5% protection reported during its phase-three clinical trials. | Moderna’s two-dose Covid-19 vaccine boasts a high efficacy rate of 93% six months after the administration of its second shot, barely waning from the 94.5% protection reported during its phase-three clinical trials. |
| The pharma company also said that it is “making progress on enrolling patients in our rare disease programs, and we are fully enrolled in our personalized cancer vaccine trial.” | The pharma company also said that it is “making progress on enrolling patients in our rare disease programs, and we are fully enrolled in our personalized cancer vaccine trial.” |
| It also said its phase-two study of its authorized Covid-19 vaccine for children between 6 months and 12 years was ongoing. So far, the study is being carried out on 4,000 children between 6 and 12, while dosage selection studies are still underway for younger age groups. | It also said its phase-two study of its authorized Covid-19 vaccine for children between 6 months and 12 years was ongoing. So far, the study is being carried out on 4,000 children between 6 and 12, while dosage selection studies are still underway for younger age groups. |
| Like this story? Share it with a friend! | Like this story? Share it with a friend! |
Previous version
1
Next version